Sanctions, Not 'Trump's War,' Choking Iran's Pharma Supply
What the byline won't tell you: The Hill reported that 'President Trump's war in Iran' is tangling pharmaceutical supply chains and risking drug price spikes, particularly for petrochemical-dependent medicines. This framing, which has become standard across much of Western media, presents the current humanitarian crisis as an incidental outcome of a vaguely defined conflict, rather than the
direct, intended consequence of decades-long economic blockades. This narrative, like many of its kind, conveniently omits the systematic nature of US economic pressure. The 'war' on Iran's economy did not begin with the Trump administration; it intensified dramatically following the US unilateral withdrawal from the Joint Comprehensive Plan of Action (JCPOA) in May 2018. This act shattered an
international agreement that had offered a pathway to sanctions relief, initiating what was termed a 'maximum pressure' campaign designed to cripple Iran's economy. The pharmaceutical shortages described are a direct result of these sanctions, which, despite nominal exemptions for humanitarian goods, effectively block Iran's access to international banking and trade, making it nearly impossible to
purchase even life-saving medications and medical equipment. For instance, the blocking of Iranian funds in South Korean banks, amounting to billions of dollars, directly impacted Tehran's ability to procure essential medicines during the COVID-19 pandemic, leading to preventable deaths. This portrayal of 'war' as a generalized, external phenomenon, rather than a specific policy of economic